Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Weight-loss drugs ... $2,575 on average. Factors contributing to higher health care costs include demand for pricey ...

Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Leigh-Anne Lagden, 26, opened up about being hospitalized after accidentally overdosing on knockoff weight loss injections ...

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as ...

Its above-average dividend yield gives investors an ... such as Zepbound and Wegovy, there could be an even bigger opportunity for weight loss pills. Pfizer has a pill it's developing called ...

Osteoarthritis of the knee is a common and often painful condition affecting millions worldwide, especially older adults. As ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...